Urinary interleukin-2 monitoring during prolonged bacillus Calmette- Guerin treatment: Can it predict the optimal number of instillations?

Journal of Urology

Volumn 161, Issue 1, 1999, Pages 67-71

  De Reijke, Theo M ^a   De Boer, Elizabeth C ^a   Kurth, Karl Heinz ^a   Schamhart, Denis H J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

BCG; Bladder neoplasms; Interleukin 2; Urine; Vaccine

Indexed keywords

BCG VACCINE; INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; TRANSITIONAL CELL CARCINOMA;

EID: 0032852808     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62065-2     Document Type: Article

References (33)

1. Kurth, K. H., Denis, L., Bouffioux, Ch., Sylvester, R., Debruyne, F. M. J., Pavone Macaluso, M. and Oosterlinck, W.: Factors affecting recurrence and progression in superficial bladder tumors. Eur. J. Cancer, 31: 1840, 1995.
2. Lundholm, C., Norlén, B. J., Ekman, P., Jahnson, S., Lagerkvist, M., Lindeborg, T., Olsson, J. O., Tveter, K., Wijkström, H., Westberg, R. and Malmström, P.-U.: A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J. Urol., 156: 372, 1996.
3. Krege, S., Giani, G., Meyer, R., Otto, T., Rübben, H. and participating clinics: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J. Urol., 156: 962, 1996.
4. Vegt, P. D. J., Witjes, J. A., Witjes, W. P. J., Doesburg, W. H., Debruyne, F. M. J. and van der Meijden, A. P.: A randomized study of intravesical mitomycin C, bacillus Calmette-Guérin Tice and bacillus Calmette-Guérin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J. Urol., 153: 929, 1995.
5. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Jr., Sullivan, J., Sarosdy, M. F., Crissman, J. D. and Coltman, C. A.: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional cell carcinoma of the bladder. New Engl. J. Med., 325: 1205, 1991.
6. Lamm, D. L.: BCG immunotherapy for transitional cell carcinoma in situ of the bladder. Oncology, 9: 947, 1995.
7. Pagano, F., Bassi, P., Milani, C., Piazza, N., Meneghini, A. and Garbeglio, A.: BCG in superficial bladder cancer: a review of phase III European trials. Eur. Urol., suppl., 21: 7, 1992.
8. Melekos, M. D., Zarakovitis, I. E., Fokaefs, E. D., Dandinis, K., Chionis, H., Bouropoulos, C. and Dauaher, H.: Intravesical bacillus Calmette-Guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumors. Oncology, 53: 281, 1996.
9. Torrence, R. J., Kavoussi, L. R., Catalona, W. J. and Ratliff, T. L.: Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. J. Urol., 139: 941, 1988.
10. Fleischmann, J. D., Toossi, Z., Einer, J. J., Wentworth, D. B., Ratliff, T. L. and Imbembo, A. L.: Urinary interleukins in patients receiving intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. Cancer, 64: 1447, 1989.
11. de Reijke, T. M., de Boer, E. C., Kurth, K. H. and Schamhart, D. H. J.: Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J. Urol., 155: 477, 1996.
12. Saint, F., Patard, J.-J., Hoznek, A., Maillé, P., Abbou, C. and Chopin, D.: Prognosis value of a Th1 urinary cytokine response following intravesical BCG treatment. J. Urol., part 2, 157: 386, abstract 1511, 1997.
13. Lamm, D. L., Crawford, E. D., Blumenstein, B., Crissman, J. D., Montie, J., Gottesman, J., Lowe, B., Sarosdy, M. F., Bohl, R. D., Weems, W. L., Grossman, H. B., Smith, J. A., Beck, T. M., Leimert, J. and Coltman, C. A.: Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group study. J. Urol., part 2, 147: 274, abstract 242, 1992.
14. Jackson, A. M., Alexandroff, A. B., Kelly, R. W., Skibinska, A., Esuvaranathan, K., Prescott, S., Chisholm, G. D. and James, K.: Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin. Exp. Immunol., 99: 369, 1995.
15. El-Demiry, M. I. M., Smith, G., Ritchie, A. W. S., James, K., Cumming, J. A., Hargreave, T. B. and Chisholm, G. D.: Local immune responses after intravesical BCG treatment for carcinoma in situ. Brit. J. Urol., 60: 543, 1987.
16. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol., 147: 1636, 1992.
17. Böhle, A., Gerdes, J., Ulmer, A. J., Hofstetter, A. G. and Flad, H. D.: Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol., 144: 53, 1990.
18. De Boer, E. C., De Jong, W. H., Steerenberg, P. A., Aarden, L. A., Tetteroo, E., De Groot, E. R., van der Meijden, A. P. M., Vegt, P. D. J., Debruyne, F. M. J. and Ruitenberg, E. J.: Induction of urinary IL1, IL2, IL6, and TNF during intravesical immunotherapy with BCG in superficial bladder cancer. Cancer Immunol. Immunother., 34: 306, 1991.
19. Bettex-Galland, M., Studer, U. E., Walz, A., Dewald, B. and Baggiolini, M.: Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guérin administration. Eur. Urol., 19: 171, 1991.
20. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J. Urol., 144: 1248, 1990.
21. Fernandez-Botran, R., Sanders, V. M., Mosmann, T. R. and Vitetta, E. S.: Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. J. Exp. Med., 168: 543, 1988.
22. Scott, P.: IFN-gamma modulates the early development of TH1 and TH2 responses in a murine model of cutaneous leishmaniasis. J. Immunol., 147: 3149, 1991.
23. Yamamura, M., Utemura, K., Deans, R. J., Weinberg, K., Rea, T. H., Bloom, B. R. and Modlin, R. L.: Defining protective responses to pathogens: cytokine prophiles in leprosy lesions. Science, 254: 277, 1991.
24. Clerici, M. and Shearer, G. M.: The TH1/TH2 model of HIV infection: new insights. Immunol. Today, 15: 575, 1994.
25. McAveney, K. M., Gomella, L. G. and Lattime, E. C.: Induction of Th1- and Th2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol. Immunother., 39: 401, 1994.
26. Orme, I. M.: Immunity to mycobacteria. Curr. Opin. Immunol., 5: 497, 1993.
27. Jackson, A. M. and James, K.: Understanding the most successful immunotherapy for cancer. Immunologist, 2/6: 208, 1994.
28. O'Donnell, M. A. and DeWolf, W. C.: Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg. Oncol. Clin. N. Amer., 4: 189, 1995.
29. Tartour, E., Gey, A., Sastre-Garau, X., Lombard Surin, I., Mosseri, V. and Fridman, W. H.: Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J. Natl. Cancer Inst., 90: 287, 1998.
30. Thiounn, N., Pages, F., Flam, T., Tartour, E., Mosseri, V., Zerbib, M., Beuzeboc, P., Deneux, L., Fridman, W. H. and Debre, B.: IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol. Lett., 58: 121, 1997.
31. Tartour, E., Pannetier, C., Mathiot, C., Teillaud, J. L., Sautes, C., Kourilsky, P. and Fridman, W. H.: Prognostic value of cytokine and Fc gamma receptor assays in oncology. Immunol. Lett., 44: 145, 1995.
32. Lamm, D. L.: Optimal BCG treatment of superficial bladder cancer as defined by American trials. Eur. Urol., suppl., 21:12, 1992.
33. Lamm, D. L., Blumenstein, B., Sarosdy, M., Grossman, H. B. and Crawford, E. D.: Significant long-term patient benefit with BCG maintenance therapy: a Southwest Oncology Group study. J. Urol., part 2, 157: 213, abstract 831, 1997.